Literature DB >> 1703352

Kidney transplantation under FK 506 immunosuppression.

R Shapiro1, M Jordan, J Fung, J McCauley, J Johnston, Y Iwaki, A Tzakis, T Hakala, S Todo, T E Starzl.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1703352      PMCID: PMC2979325     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  16 in total

1.  Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.

Authors:  J J Fung; S Todo; A Jain; J McCauley; M Alessiani; C Scotti; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

2.  The side effects of FK 506 in humans.

Authors:  R Shapiro; J J Fung; A B Jain; P Parks; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

3.  The effects of FK 506 on renal function after liver transplantation.

Authors:  J McCauley; J Fung; A Jain; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

4.  Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations.

Authors:  A B Jain; R Venkataramanan; E Cadoff; J J Fung; S Todo; A Krajack; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

5.  Oral glucose tolerance test in liver recipients treated with FK 506.

Authors:  L Mieles; S Todo; J J Fung; A Jain; H Furukawa; M Susuki; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

Review 6.  Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics.

Authors:  T E Starzl; K Abu-Elmagd; A Tzakis; J J Fung; K A Porter; S Todo
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

7.  Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients.

Authors:  L Mieles; R D Gordon; D Mintz; R M Toussaint; O Imventarza; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

8.  A highly sensitive method to assay FK-506 levels in plasma.

Authors:  K Tamura; M Kobayashi; K Hashimoto; K Kojima; K Nagase; K Iwasaki; T Kaizu; H Tanaka; M Niwa
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

9.  Kidney transplantation under FK 506.

Authors:  T E Starzl; J Fung; M Jordan; R Shapiro; A Tzakis; J McCauley; J Johnston; Y Iwaki; A Jain; M Alessiani
Journal:  JAMA       Date:  1990-07-04       Impact factor: 56.272

10.  The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients.

Authors:  J P Boudreaux; L McHugh; D M Canafax; N Ascher; D E Sutherland; W Payne; R L Simmons; J S Najarian; D S Fryd
Journal:  Transplantation       Date:  1987-09       Impact factor: 4.939

View more
  34 in total

1.  Intravenous, oral pharmacokinetics, and oral dosing of FK 506 in small bowel transplant patients.

Authors:  A Jain; R Venkataramanan; S Todo; K Abu-Elmagd; J Fung; V Warty; A Tzakis; J Reyes; M Alessiani; T E Starzl
Journal:  Transplant Proc       Date:  1992-06       Impact factor: 1.066

Review 2.  FK 506 and autoimmune disease: perspective and prospects.

Authors:  A W Thomson; T E Starzl
Journal:  Autoimmunity       Date:  1992       Impact factor: 2.815

3.  The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation.

Authors:  J J Fung; M Eliasziw; S Todo; A Jain; A J Demetris; J P McMichael; T E Starzl; P Meier; A Donner
Journal:  J Am Coll Surg       Date:  1996-08       Impact factor: 6.113

4.  Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) induction.

Authors:  A C Tsamandas; S M Pham; E C Seaberg; O Pappo; R L Kormos; A Kawai; B P Griffith; A Zeevi; R Duquesnoy; J J Fung; T E Starzl; A J Demetris
Journal:  J Heart Lung Transplant       Date:  1997-07       Impact factor: 10.247

5.  Renal transplantation under FK 506 in patients with previous loss of renal function due to hemolytic uremic syndrome.

Authors:  J McCauley; R Shapiro; O Bronster; M Jordan; D Ellis; N Gilboa; V Scantlebury; C Jensen; A Jain; T Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

6.  FK 506 versus cyclosporine in pediatric liver transplantation.

Authors:  A G Tzakis; J Reyes; S Todo; M Green; T Ohya; A Jain; K Abu-Elmagd; M Alessiani; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

7.  FK 506 in clinical kidney transplantation.

Authors:  R Shapiro; M Jordan; V Scantlebury; J Fung; C Jensen; A Tzakis; J McCauley; P Carroll; C Ricordi; A J Demetris
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

8.  FK 506 conversion of renal allografts failing cyclosporine immunosuppression.

Authors:  M L Jordan; R Shapiro; C W Jensen; V Scantlebury; J Fung; A Tzakis; J McCauley; A Jain; J Demetrius; P Randhawa
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

9.  Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium.

Authors:  M L Jordan; S Hignet; J Wright; R A Hoffman; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

Review 10.  Metabolic Disorders with Kidney Transplant.

Authors:  Elizabeth Cohen; Maria Korah; Glenda Callender; Renata Belfort de Aguiar; Danielle Haakinson
Journal:  Clin J Am Soc Nephrol       Date:  2020-04-13       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.